MX2021015717A - Metodos para prever la respuesta al farmaco en pacientes con cancer. - Google Patents
Metodos para prever la respuesta al farmaco en pacientes con cancer.Info
- Publication number
- MX2021015717A MX2021015717A MX2021015717A MX2021015717A MX2021015717A MX 2021015717 A MX2021015717 A MX 2021015717A MX 2021015717 A MX2021015717 A MX 2021015717A MX 2021015717 A MX2021015717 A MX 2021015717A MX 2021015717 A MX2021015717 A MX 2021015717A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- patient
- cancer patients
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000004043 responsiveness Effects 0.000 title 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 abstract 2
- 229950005778 dovitinib Drugs 0.000 abstract 2
- 230000014509 gene expression Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Abstract
La presente invención se refiere a métodos, dispositivos y kits para detectar la expresión génica en un paciente con un cáncer o determinar la respuesta de un paciente con un cáncer a un tratamiento, tal como tratamiento con dovitinib o una sal de esta aceptable desde el punto de vista farmacéutico. La invención incluye además métodos para tratar a un paciente con un cáncer mediante la administración de un tratamiento, por ejemplo, tratamiento con dovitinib o una sal de esta aceptable desde el punto de vista farmacéutico, en particular cuando se determina que el paciente responde al tratamiento basado en la expresión de los biomarcadores descritos en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/444,881 US10835531B1 (en) | 2019-06-18 | 2019-06-18 | Methods for predicting drug responsiveness in cancer patients |
PCT/EP2020/066724 WO2020254383A1 (en) | 2019-06-18 | 2020-06-17 | Methods for predicting drug responsiveness in cancer patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015717A true MX2021015717A (es) | 2022-04-11 |
Family
ID=71105475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015717A MX2021015717A (es) | 2019-06-18 | 2020-06-17 | Metodos para prever la respuesta al farmaco en pacientes con cancer. |
Country Status (9)
Country | Link |
---|---|
US (2) | US10835531B1 (es) |
EP (1) | EP3987063A1 (es) |
JP (1) | JP2022537265A (es) |
CN (1) | CN114258432A (es) |
AU (1) | AU2020294893A1 (es) |
BR (1) | BR112021025390A8 (es) |
CA (1) | CA3142558A1 (es) |
MX (1) | MX2021015717A (es) |
WO (1) | WO2020254383A1 (es) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
US20020006613A1 (en) | 1998-01-20 | 2002-01-17 | Shyjan Andrew W. | Methods and compositions for the identification and assessment of cancer therapies |
US7324926B2 (en) | 1999-04-09 | 2008-01-29 | Whitehead Institute For Biomedical Research | Methods for predicting chemosensitivity or chemoresistance |
US20020120004A1 (en) | 2000-02-17 | 2002-08-29 | Roth Frederick P. | Methods and compositions for the identification, assessment, prevention and therapy of human cancers |
AU9327501A (en) | 2000-09-11 | 2002-03-26 | Chiron Corp | Quinolinone derivatives |
WO2005032347A2 (en) | 2003-10-01 | 2005-04-14 | The Ohio State University Research Foundation | Determining the chemosensitivity of cells to cytotoxic agents |
US7879545B2 (en) | 2003-11-05 | 2011-02-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier |
US20050227266A1 (en) | 2004-02-06 | 2005-10-13 | Ross Douglas T | Biomarker:compound correlations in cancer diagnosis and therapy |
CN101326292A (zh) * | 2005-12-08 | 2008-12-17 | 诺瓦提斯公司 | Fgfr3抑制物对基因转录的影响 |
JP5914362B2 (ja) | 2010-02-11 | 2016-05-11 | ナノストリング テクノロジーズ, インコーポレイテッド | 低分子rna分子の検出のための組成物および方法 |
US20110229888A1 (en) | 2010-03-16 | 2011-09-22 | Hengen Paul N | Compositions and Methods for the Detection of Genomic Features |
AR081776A1 (es) | 2010-06-30 | 2012-10-17 | Novartis Ag | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion |
AU2012272763B2 (en) | 2011-06-24 | 2016-11-03 | Nanostring Technologies, Inc. | Multivariate diagnostic assays and methods for using same |
WO2015160986A2 (en) * | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
-
2019
- 2019-06-18 US US16/444,881 patent/US10835531B1/en active Active
-
2020
- 2020-06-17 AU AU2020294893A patent/AU2020294893A1/en not_active Abandoned
- 2020-06-17 EP EP20733593.6A patent/EP3987063A1/en active Pending
- 2020-06-17 US US17/596,711 patent/US20220362240A1/en active Pending
- 2020-06-17 JP JP2021572630A patent/JP2022537265A/ja active Pending
- 2020-06-17 WO PCT/EP2020/066724 patent/WO2020254383A1/en unknown
- 2020-06-17 BR BR112021025390A patent/BR112021025390A8/pt unknown
- 2020-06-17 MX MX2021015717A patent/MX2021015717A/es unknown
- 2020-06-17 CN CN202080058332.9A patent/CN114258432A/zh active Pending
- 2020-06-17 CA CA3142558A patent/CA3142558A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020294893A1 (en) | 2021-12-09 |
BR112021025390A8 (pt) | 2022-11-08 |
CA3142558A1 (en) | 2020-12-24 |
CN114258432A (zh) | 2022-03-29 |
BR112021025390A2 (pt) | 2022-02-01 |
US20220362240A1 (en) | 2022-11-17 |
US10835531B1 (en) | 2020-11-17 |
EP3987063A1 (en) | 2022-04-27 |
JP2022537265A (ja) | 2022-08-25 |
WO2020254383A1 (en) | 2020-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008581A (es) | Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos. | |
MX2015007714A (es) | Agente terapeutico de direccionamiento a glipicano 3 (gpc3) que es administrado a pacientes para quienes la terapia con agentes terapeuticos de direccionamiento a gpc3 es eficaz. | |
MX2016006252A (es) | Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono. | |
EP4012415A3 (en) | Methods and compositions related to toxicity associated with cell therapy | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
JP2018515618A5 (es) | ||
NZ716473A (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
MX2018011349A (es) | Uso de masitinib para el tratamiento de una subpoblacion de pacientes con esclerosis lateral amiotrofica. | |
WO2020186132A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
EA201500373A1 (ru) | Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор | |
UA124238U (uk) | Спосіб лікування раку молочної залози | |
WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
BR112021022789A2 (pt) | Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a | |
MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
EA201700123A1 (ru) | Способ прогнозирования варианта лекарственного препарата для лечения депрессии | |
MX2017013390A (es) | Método para el tratamiento de cáncer pulmonar. | |
EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
MX2021000133A (es) | Uso de compuestos conocidos como inhibidores de la d-aminoacido oxidasa. | |
MX2014000204A (es) | Metodo de administracion y tratamiento. | |
BR112017011663A2 (pt) | dispensador de insulina, método de controle dos níveis de glicose em um paciente, e, sistema. | |
BR112017003552A2 (pt) | ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total? | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
MX2021015717A (es) | Metodos para prever la respuesta al farmaco en pacientes con cancer. |